Oxford Nanopore Technologies

In this monthly series, we share a selection of recent publications that use Oxford Nanopore sequencing to unlock novel insights. Spanning gene therapy, cancer, and infectious disease, these studies showcase the advances in scientific research made possible by Oxford Nanopore sequencing. Featured in this edition: 1. Comprehensive profiling of gene therapy vectors 2. Resolving structural variants linked to cancer risk 3. Tackling antibiotic resistance in the NHS with 16S sequencing 4.

Oxford Nanopore Technologies has been named winner of the 2026 MacRobert Award, the UK's longest-running and most prestigious prize for engineering innovation, in recognition of its pioneering nanopore sequencing technology and its global impact. The award was presented on 8 July by HRH The Princess Royal, Royal Fellow of the Royal Academy of Engineering, at the Academy Awards Dinner in London.

Why is scalable long-read sequencing biopharma’s new priority? Cell and gene therapies hold extraordinary promise for tackling previously untreatable diseases. However, the same tools that enable these breakthroughs, such as adeno-associated virus (AAV) vectors, CRISPR-Cas9, and other genome-editing methods, also carry risk.

Complex diseases are shaped by polygenic risk, regulatory variation, and molecular mechanisms that cannot be fully explained by single-omics approaches. In this webinar, our expert speakers will discuss how multiomic Oxford Nanopore sequencing supports a deeper understanding of disease mechanisms, by integrating DNA, RNA, and epigenetic analysis — all on a single platform. PLEASE NOTE: This webinar will be offered in two timezones. Please select your preferred option on the form below.

Melbourne, Australia, and Oxford, UK, 8 July 2026 – Victorian Clinical Genetics Services (“VCGS”) has received National Association of Testing Authorities (NATA) accreditation to ISO 15189 for a clinical whole genome sequencing workflow incorporating Oxford Nanopore sequencing technology.

Oxford Nanopore sequencing offers a unique multiomic solution for cancer research and precision oncology. With real-time analysis of native DNA and RNA fragments of any length, capture previously hidden variants and modifications in a single consolidated assay. Why choose Oxford Nanopore?

Fast and accurate identification and characterisation of microbes is vital to guide public health, food safety, and clinical research to prevent the spread of pathogenic microbes. With Oxford Nanopore sequencing, you can get access to real-time data and generate rapid insight to time-critical results, meaning you can make changes in real time and ensure each experiment runs with confidence. High-quality meets complete.

In this monthly series, we share a selection of recent publications that use Oxford Nanopore sequencing to unlock novel insights. Spanning pathogen metagenomics, outbreak monitoring, and leukaemia classification, these studies showcase the advances in scientific research made possible by Oxford Nanopore sequencing. At our flagship conference, London Calling, many researchers presented work that was hot off the press, and we’ve chosen a few of the highlights to share here.

London, 15th June 2026 – Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, has been named a finalist for the 2026 MacRobert Award, the longest-running and most prestigious prize for UK engineering innovation. Presented by the Royal Academy of Engineering, the Award recognises groundbreaking engineering achievements that combine commercial success with societal benefit.

Oxford, UK, and Oslo, Norway, 15 June 2026 – Oxford Nanopore Technologies and MATRIX, Norway’s national cancer research centre, today announced the expansion of their collaboration to implement Oxford Nanopore sequencing for national central nervous system (CNS) tumour classification.